LOX-PP–Hsp70–cRaf interactions resulted in reduced Erk1/2 signaling, which is Ras/c-Raf pathway-dependent, and consistent with the tumor growth inhibitory properties of LOX-PP. Here, LOX is linked to neoplasm.